Unknown

Dataset Information

0

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.


ABSTRACT: The clinical efficacy of chimeric antigen receptor (CAR)-redirected T cells remains marginal in solid tumors compared with leukemias. Failures have been attributed to insufficient T-cell migration and to the highly immunosuppressive milieu of solid tumors. To overcome these obstacles, we have combined CAR-T cells with an oncolytic virus armed with the chemokine RANTES and the cytokine IL15, reasoning that the modified oncolytic virus will both have a direct lytic effect on infected malignant cells and facilitate migration and survival of CAR-T cells. Using neuroblastoma as a tumor model, we found that the adenovirus Ad5?24 exerted a potent, dose-dependent, cytotoxic effect on tumor cells, whereas CAR-T cells specific for the tumor antigen GD2 (GD2.CAR-T cells) were not damaged. When used in combination, Ad5?24 directly accelerated the caspase pathways in tumor cells exposed to CAR-T cells, whereas the intratumoral release of both RANTES and IL15 attracted CAR-T cells and promoted their local survival, respectively, increasing the overall survival of tumor-bearing mice. These preclinical data support the use of this innovative biologic platform of immunotherapy for solid tumors. Cancer Res; 74(18); 5195-205. ©2014 AACR.

SUBMITTER: Nishio N 

PROVIDER: S-EPMC4167556 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Nishio Nobuhiro N   Diaconu Iulia I   Liu Hao H   Cerullo Vincenzo V   Caruana Ignazio I   Hoyos Valentina V   Bouchier-Hayes Lisa L   Savoldo Barbara B   Dotti Gianpietro G  

Cancer research 20140724 18


The clinical efficacy of chimeric antigen receptor (CAR)-redirected T cells remains marginal in solid tumors compared with leukemias. Failures have been attributed to insufficient T-cell migration and to the highly immunosuppressive milieu of solid tumors. To overcome these obstacles, we have combined CAR-T cells with an oncolytic virus armed with the chemokine RANTES and the cytokine IL15, reasoning that the modified oncolytic virus will both have a direct lytic effect on infected malignant cel  ...[more]

Similar Datasets

| S-EPMC5392365 | biostudies-literature
| S-EPMC4839314 | biostudies-literature
| S-EPMC5767005 | biostudies-literature
| S-EPMC10044396 | biostudies-literature
| S-EPMC6309774 | biostudies-literature
| S-EPMC5744429 | biostudies-literature
| S-EPMC4849432 | biostudies-literature
| S-EPMC7388644 | biostudies-literature
| S-EPMC6278070 | biostudies-literature
| S-EPMC7269829 | biostudies-literature